Stabilization of platelets at ambient temperature
Formulations with pH buffers, anticoagulants, sugars, and carbohydrates stabilize platelets at ambient temperature, addressing the challenge of maintaining platelet inactivation for analysis and therapy by ensuring prolonged functionality.
Patent Information
- Application Number
- JP2022177625
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2014-06-10
- Filing Date
- 2022-11-04
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2035-06-09
AI Technical Summary
Existing methods fail to maintain platelets in an inactivated state for extended periods at ambient temperature, leading to suboptimal analysis and therapeutic applications due to activation and aggregation during storage.
Formulations comprising pH buffers, anticoagulants, non-reducing sugars, polyols, and functional carbohydrates, or halogenated disaccharide derivatives, stabilize platelets in an inactivated state for up to 24 hours at ambient temperature.
The formulations maintain at least 90% of platelets in an inactivated state for extended periods, enabling accurate analysis and therapeutic applications by preserving their functionality.
Smart Images

Figure 0007594572000001 
Figure 0007594572000002 
Figure 0007594572000003
Abstract
Description
[Technical field]
[0001] (cross reference) This application claims the benefit of U.S. Provisional Patent Application No. 62 / 010,151, filed Jun. 10, 2014, which is incorporated herein by reference in its entirety.
[0002] The present invention relates generally to the stabilization of one or more platelets at ambient temperatures. In particular, the present invention relates to formulations, compositions, products, kits, and methods for the substantially stable storage of one or more metabolically active platelets at ambient temperatures. [Background technology]
[0003] Whole blood is a complex mixture of cells, nucleic acids, proteins, and various other analytes. Blood components include, but are not limited to, cells such as white blood cells (monocytes, lymphocytes, and granulocytes), red blood cells, platelets, and circulating tumor cells; nucleic acid molecules such as circulating free DNA (cfDNA); polypeptides such as lipoproteins, albumin, and serum proteins, and various other analytes.
[0004] Platelets or thrombocytes are anucleated cells that play a key role in blood clotting. Platelets are small, disc-shaped cells that circulate in mammalian blood and are involved in hemostasis. Platelets secrete a wide variety of growth factors that help promote blood clotting and tissue regeneration.
[0005] The level of circulating platelets in healthy individuals is approximately (150-400) × 10 3 They are controlled within physiological ranges of per cubic millimeter. Suboptimal levels of platelets (thrombocytopenia) can lead to excessive bleeding, while levels above optimal concentrations can lead to the formation of thromboli (blood clots), which can block blood vessels and increase the risk of stroke, pulmonary embolism, or myocardial infarction.
[0006] Circulating platelets typically exist in an inactivated state and are maintained in that state by factors induced by the endothelial cells lining the lumen of blood vessels. Upon disruption or damage to this endothelial layer, platelets come into contact with collagen or von Willebrand factor, which activates the platelets and leads to platelet aggregation (i.e., clot formation). This activation and aggregation can also occur through the enzymatic activity of thrombin or in the presence of ADP. Upon activation, platelets release the contents of their alpha and dense granules, including growth factors and fibrinogen, which promote clot formation and aid in promoting fibroblast recruitment, thereby facilitating wound healing. Activated platelets can be distinguished from inactivated platelets by their more spherical / stellate shape.
[0007] During collection of whole blood, activation, aggregation, and / or release of numerous growth factors and other intracellular components of platelets can significantly interfere with quantification and analysis of these cells. Addition of various anticoagulants to maintain inactivated platelets at ambient temperature only maintains approximately 13-52% of inactivated platelets at the 24-hour time point, making accurate quantitative analysis of total platelets virtually impossible at this time point. Thus, there is a need for improved formulations and methods that stabilize platelets at ambient temperature for a time sufficient for storage and transport of platelets for research, diagnostic, and therapeutic purposes. Summary of the Invention
[0008] The formulations, compositions, and methods of the present invention advantageously provide stabilization of platelets at ambient temperature, where these cells remain functional and retain the ability to activate for at least 24 hours after blood collection, significantly increasing the time of storage and transport of substantially stable platelets for research, diagnostic, and potential therapeutic applications. In some embodiments, formulations for substantially stable storage of one or more platelets at ambient temperature are disclosed herein, whereby one or more platelets are stabilized for at least 6 hours. In some embodiments, one or more platelets are stabilized in an inactivated state. In some embodiments, one or more platelets are present in a blood sample. In some embodiments, one or more platelets are present in an inactivated state in a blood sample. In some embodiments, one or more platelets are isolated from a blood sample. In some embodiments, at least 90% of the platelets are stabilized in an inactivated state for at least 6 hours. In some embodiments, at least 90% of the platelets are stabilized in an inactivated state for at least 9 hours. In some embodiments, the platelets are stabilized in an inactivated state for at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours, or at least 24 hours. In some embodiments, the formulation comprises: (i) a pH buffer; (ii) an anticoagulant; (iii) at least one non-reducing sugar or polyol; and (iv) a functionalized carbohydrate. In some embodiments, the formulation comprises a polyol selected from the group consisting of glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, adonitol, mannitol, sorbitol, galactitol, fucitol, iditol, and inositol, and combinations thereof. In some embodiments, the polyol is a pentose polyol or a hexose polyol.In some embodiments, the pentose polyol is adonitol. In some embodiments, the functional carbohydrate is sucralfate or sucrose octasulfate. In some embodiments, the functional carbohydrate is sucrose octasulfate. In some embodiments, the non-reducing sugar is sucrose or trehalose. In some embodiments, the non-reducing sugar is trehalose. In some embodiments, the anticoagulant is EDTA or hirudin. In some embodiments, the pH buffer is 2x phosphate buffered saline or Tris-HCl.
[0009] In one aspect of the present invention, a formulation is provided for the substantially stable storage of one or more platelets in an inactivated state in a blood sample at ambient temperature, whereby one or more platelets are stabilized in an inactivated state for at least 6 hours. In some embodiments, at least 90% of the platelets are stabilized in an inactivated state for at least 6 hours. In some embodiments, the platelets are stabilized in an inactivated state for at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours, or at least 24 hours. In certain embodiments, the formulation comprises (i) a pH buffer, (ii) an anticoagulant, (iii) at least one non-reducing sugar or polyol, and (iv) a functional carbohydrate. In some embodiments, the polyol is selected from the group consisting of glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, adonitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, and combinations thereof. In some embodiments, the polyol is a pentose polyol or a hexose polyol. In some embodiments, the polyol is adonitol. In some embodiments, the functional carbohydrate is sucrose octasulfate. In some embodiments, the functional carbohydrate is sucrose octasulfate. In some embodiments, the non-reducing sugar is sucrose or trehalose. In some embodiments, the non-reducing sugar is trehalose. In some embodiments, the anticoagulant is EDTA or hirudin. In some embodiments, the anticoagulant is EDTA, the functional carbohydrate is sucrose octasulfate, and the non-reducing sugar is sucrose or trehalose. In yet another embodiment, the anticoagulant is EDTA, the functional carbohydrate is sucrose octasulfate, and the non-reducing sugar is trehalose.In some embodiments, the pH buffer is 2x phosphate buffered saline or Tris-HCl. In some embodiments, a formulation for substantially stable storage of one or more platelets at ambient temperature is disclosed herein, comprising a halogenated disaccharide derivative and an anticoagulant, whereby the one or more platelets are stabilized for at least 6 hours. In some embodiments, the one or more platelets are stabilized in an inactivated state. In some embodiments, the one or more platelets are present in a blood sample. In some embodiments, the one or more platelets are present in an inactivated state in a blood sample. In some embodiments, the one or more platelets are isolated from the blood sample. In some embodiments, the anticoagulant is hirudin. In some embodiments, the halogenated disaccharide derivative is selected from the group consisting of sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside), trichloronated maltose, 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside, 1,6-sichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside, and combinations thereof. In some embodiments, the formulation consists essentially of hirudin and sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside).
[0010] In some embodiments, a formulation for substantially stable storage of one or more platelets in an inactivated state in a blood sample at ambient temperature is provided, comprising a halogenated disaccharide derivative, wherein the one or more platelets are stabilized in an inactivated state for at least six hours. In some embodiments, the halogenated disaccharide derivative is preferably sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside) trichloronate maltose, 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside, and 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside, and more preferably the halogenated disaccharide derivative is sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside). In some embodiments, the formulation further comprises an anticoagulant, preferably hirudin. In some embodiments, the anticoagulant is hirudin. In some embodiments, the formulation consists essentially of hirudin and sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside).
[0011] In some embodiments, one or more substantially stably stored platelet compositions are disclosed herein, comprising one or more platelets mixed with the disclosed formulation.In some embodiments, one or more platelets are present in a blood sample.In some embodiments, one or more platelets are isolated platelets.In some embodiments, one or more platelets are inactivated.
[0012] In some embodiments, disclosed herein is an article of manufacture comprising a formulation described herein contained within a blood collection tube. In some embodiments, the blood collection tube is an evacuated blood collection tube.
[0013] Disclosed herein in some embodiments is a kit comprising the products and package inserts described herein.
[0014] In some embodiments, disclosed herein are methods for substantially stably storing one or more platelets at ambient temperature, the methods comprising: mixing one or more platelets from a subject with a formulation provided herein, wherein the one or more platelets are stabilized for at least 6 hours. In some embodiments, the one or more platelets are stabilized in an inactivated state. In some embodiments, the one or more platelets are a blood sample from the subject. In some embodiments, the one or more platelets are stabilized in an inactivated state in a blood sample from the subject. In some embodiments, the one or more platelets are isolated from a blood sample from the subject. In some embodiments, at least 90% of the platelets are stabilized in an inactivated state for at least 6 hours. In some embodiments, at least 90% of the platelets are stabilized in an inactivated state for at least 9 hours. In some embodiments, the method further comprises activating the one or more inactivated platelets by adding an activating agent that promotes aggregation of the platelets. In some embodiments, the activating agent is ADP. In some embodiments, the method further comprises activating the one or more platelets by adding an activating agent that promotes aggregation of the platelets. In some embodiments, the activating agent is ADP. In some embodiments, the subject is an animal. In some embodiments, the subject is a mammal. In some embodiments, the mammal is a human.
[0015] In some embodiments, disclosed herein is a method for substantially stably storing one or more inactivated platelets in a blood sample at ambient temperature, comprising mixing one or more platelets from a subject with a formulation provided herein, whereby one or more platelets are stabilized in an inactivated state for at least 6 hours. In some embodiments, at least 90% of the platelets are stabilized in an inactivated state for at least 6 hours. In some embodiments, the platelets are stabilized in an inactivated state for at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours, or at least 24 hours. In some embodiments, the blood sample is mixed with the stabilizing formulation when the blood sample is collected from the subject to substantially stabilize one or more platelets in an inactivated state after collection from the subject. In some embodiments, the method further comprises activating one or more platelets by adding an activating agent. In some embodiments, the activator is ADP. In further embodiments of the method, the subject is an animal, more preferably a mammal, and even more preferably a human.
[0016] The present invention relates to formulations, compositions, products, kits, and methods for the substantially stable storage of one or more platelets at ambient temperature. In some embodiments, one or more platelets are stored in a blood sample in an inactivated state but capable of activation. In one aspect, the formulations described herein advantageously maintain the integrity of the inactivated, metabolically active platelets, which can then be analyzed for activation or used in therapeutic applications to promote blood clotting in a patient.
[0017] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to a "method" includes one or more methods, and / or types of steps described herein that will be apparent to those skilled in the art upon reading this disclosure, etc.
[0018] As used herein, "about" when referring to a measurable value such as an amount, temporal duration, and the like, is meant to encompass a variation of ±20%, or ±10%, or ±5%, or ±1% from the specified value, where such variations are appropriate for the disclosed compositions or for practicing the disclosed methods.
[0019] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents, patent applications, and publications cited herein are incorporated by reference in their entirety.
[0020] In some embodiments, a formulation is provided for substantially stable storage of metabolically active platelets at ambient temperature. In some embodiments, the platelets are isolated from a blood sample. In some embodiments, the platelets are present in a blood sample. In some embodiments, the platelets are inactivated. In certain embodiments, the platelet stabilizing formulation comprises a pH buffer, an anticoagulant, a non-reducing sugar, a polyol, and a functional carbohydrate. In certain other embodiments, the platelet stabilizing formulation comprises a pH buffer, an anticoagulant, a polyol, and a functional carbohydrate. In certain other embodiments, the stabilizing formulation comprises a pH buffer, an anticoagulant, a non-reducing sugar, and a functional carbohydrate. In yet another embodiment, the stabilizing formulation comprises a halogenated disaccharide derivative, and an anticoagulant. In yet another embodiment, the stabilizing formulation comprises a halogenated disaccharide derivative, an anticoagulant, and a pH buffer. The formulation is capable of stabilizing at least 60%, 70%, 80%, or 90% of the inactivated, metabolically active platelets in a blood sample for at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours, or at least 24 hours at ambient temperature.
[0021] The term "ambient temperature" as used herein refers to typical indoor room temperature. In some embodiments, the ambient temperature is between 15 and 32° C. In some embodiments, the ambient temperature is between 20 and 27° C.
[0022] In another aspect of the invention, a formulation is provided for the substantially stable storage of inactivated, metabolically active platelets in a blood sample at ambient temperature. In certain embodiments, the platelet stabilizing formulation comprises a pH buffer, an anticoagulant, a non-reducing sugar, a polyol, and a functional carbohydrate. In certain other embodiments, the platelet stabilizing formulation comprises a pH buffer, an anticoagulant, a polyol, and a functional carbohydrate. In certain other embodiments, the stabilizing formulation comprises a pH buffer, an anticoagulant, a non-reducing sugar, and a functional carbohydrate. In yet another embodiment, the stabilizing formulation comprises a halogenated disaccharide derivative and an anticoagulant. In yet a further embodiment, the stabilizing formulation comprises a halogenated disaccharide derivative, an anticoagulant, and a pH buffer. The formulation is capable of stabilizing at least 60%, 70%, 80%, or 90% of the inactivated, metabolically active platelets in a blood sample for at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours, or at least 24 hours at ambient temperature.
[0023] In another aspect, provided herein is a composition in which a blood sample is mixed with a platelet stabilizing formulation to generate one or more substantially stabilized inactivated platelets in the preparation of whole blood. In yet another embodiment, provided is a composition comprising one or more purified or substantially purified platelets mixed with a stabilized formulation of the invention. Formulation Reagents A.pH buffer According to certain embodiments, the formulations and compositions for the substantially stable preservation of one or more platelets described herein include one or more pH buffers. In some embodiments, the pH buffer is any of a number of compounds known in the art for their ability to resist changes in pH of a solution, such as an aqueous solution, in which the pH buffer is present. The selection of one or more pH buffers to be included in the composition for stable preservation is made based on the disclosures herein and routine practice in the art, and may be influenced by a variety of factors, including the pH desired to be maintained, the condition of the biological sample, the state of the solvent used, other components of the formulation used, and other criteria. For example, typically, pH buffers are used at pH within about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 pH units of the proton dissociation constant (pKa) characteristic of the buffer.
[0024] Non-limiting examples of pH buffers include citric acid, tartaric acid, malic acid, sulfosalicylic acid, sulfoisophthalic acid, oxalic acid, borate, CAPS (3-(cyclohexylamino)-1-propanesulfonic acid), CAPSO (3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid), EPPS (4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid), HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), MOPSO (3-morpholino-2-hydroxypropanesulfonic acid), PIPES (1,4-piperazinediethanesulfonic acid), TAPS (N-[tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid), TAPSO (2-hydroxy-3-[tris(hydroxymethyl)methylamino]-1-propanesulfonic acid), TES (N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid), bicine (N,N-bis(2-hydroxyethyl)glycine), tricine (N-[tris(hydroxymethyl)methyl]glycine), tris(tris(hydroxymethyl)aminomethane), and bis-tris(2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)-1,3-propanediol). In some embodiments, any of those shown in Table 1 have a pH of about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, or 9.0. B. Polyol Similarly, as described herein, certain embodiments include at least one polyol in a composition for substantially stable preservation of viable, inactivated platelets in a whole blood sample at ambient temperature. Polyols are polyhydric alcohols containing two or more hydroxyl groups and have the general formula H(CHOH) n H, where n is an integer selected from 2 to 7, inclusive. Polyols vary in chain length, with most polyols having 5- or 6-carbon chains derived from pentoses (five carbon sugars) and hexoses (six carbon sugars); however, shorter and longer carbon chain polyols also exist. Representative polyols include, but are not limited to, glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, adonitol, mannitol, sorbitol, galactitol, fucitol, iditol, and inositol. The selection of one or more particular polyols to be included in the substantially stable storage composition is made based on the disclosure herein and routine practice in the art, and may be influenced by a variety of factors, including other formulation ingredients. In some embodiments, the polyol present in the formulation is a pentose polyol. In some embodiments, the polyol is adonitol. In some embodiments, the polyol is present at a concentration between 20-100 mM, or between 25-75 mM. In some embodiments, the polyol is a pentose polyol and is present at a concentration between 20-100 mM, or between 25-75 mM, hi some embodiments, the polyol is adonitol and is present at a concentration between 20-100 mM, or between 25-75 mM. C. Disaccharide derivatives In certain embodiments, a formulation or composition for substantially stable storage of one or more inactivated platelets in a whole blood sample at ambient temperature, including those in Table 1, comprises at least one halogenated disaccharide derivative. In some embodiments, the halogenated disaccharide derivative is a dichlorinated or trichlorinated disaccharide. In some embodiments, such dichlorinated or trichlorinated disaccharides, alone or in the presence of only a buffer, unexpectedly provide substantially stable storage of inactivated platelets. Halogenated disaccharide derivatives, see, for example, US Patent Publication No. 2014 / 0065062, include sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside), trichlorinated maltose, 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside, and 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside. The selection of one or more halogenated disaccharide derivatives to be included in the substantially storage stable composition is made based on the disclosure herein and routine practice in the art, and may be influenced by a variety of factors, including other formulation ingredients. In some embodiments, the functional carbohydrate is sucralose and is present at about 1.0-50.0 mM. In some embodiments, the functional carbohydrate is sucralose and is present at about 10.0-30.0 mM. In some embodiments, the functional carbohydrate is sucralose and is present at about 25.0 mM. D. Functional carbohydrates In some embodiments described herein, the formulations, including those in Table 1, include a functional carbohydrate. Exemplary functional carbohydrates include sucralfate or sucrose octasulfate, and from the disclosure herein, one of skill in the art will recognize that other functional carbohydrates may be selected for use in the formulations and compositions for stable storage of viable, activatable platelets, although this may vary depending on the other components of the composition utilized. In some embodiments, the concentration of the functional carbohydrate in the formulations and compositions of the invention, including those set forth in Table 1, is about 0.005-1.0 mM. In some embodiments, the concentration of the functional carbohydrate in the formulations and compositions of the invention, including those set forth in Table 1, is about 0.25-0.5 mM. E. Non-reducing sugars In some embodiments, formulations and compositions for substantially stable storage of platelets at ambient temperature include at least one non-reducing sugar. In some embodiments, formulations and compositions for substantially stable storage of viable, inactivated platelets in a whole blood sample at ambient temperature include at least one non-reducing sugar. As used herein, "non-reducing sugar" refers to a carbohydrate molecule that lacks a functional aldehyde group. Exemplary non-reducing sugars include sucrose and trehalose. In some embodiments, the non-reducing sugar is sucrose. In some embodiments, the non-reducing sugar is trehalose. In some embodiments, the trehalose is present at a concentration of about 1.0-50 mM. In some embodiments, the trehalose is present at a concentration of about 10.0-30 mM. In some embodiments, the trehalose is present at a concentration of about 25 mM. F. Anticoagulants In some embodiments, an anticoagulant is included in the formulation or composition described herein. Such anticoagulants are known in the art. Exemplary anticoagulants include ethylenediaminetetraacetic acid (EDTA), hirudin, heparin, and sodium citrate. In some embodiments, the anticoagulant is hirudin. In some embodiments, hirudin is present at a concentration of about 1.0-50 μg / mL. In some embodiments, hirudin is present at a concentration of about 1.0-25 μg / mL. In some embodiments, hirudin is present at a concentration of about 10-20 μg / mL. Typical formulations for stabilization of platelets at ambient temperature In some embodiments, the formulations, compositions, and methods of the present invention advantageously provide substantially stable storage of platelets at ambient temperature for at least 6 hours. In some embodiments, the formulations, compositions, and methods of the present invention advantageously provide substantially stable storage of platelets in a naturally circulating, inactivated state in a blood sample at ambient temperature, where the cells retain the ability to be activated after collection for at least 6 hours. In other embodiments, at least 90% of the platelets are stabilized in an inactivated state for at least 6 hours. In other embodiments, the platelets are stabilized in an inactivated state for at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours, or at least 24 hours.
[0025] In certain embodiments, the formulation for substantially stable storage of platelets at ambient temperature comprises a pH buffer, an anticoagulant, a non-reducing sugar, a polyol, and a functional carbohydrate. In certain embodiments, the stabilized formulation comprises a pH buffer, an anticoagulant, a polyol, and a functional carbohydrate. In certain embodiments, the formulation for substantially stable storage of platelets comprises a pH buffer, an anticoagulant, a non-reducing sugar, and a functional carbohydrate. In some embodiments, the formulation for substantially stable storage of platelets comprises a halogenated disaccharide derivative and an anticoagulant, and may further comprise a pH buffer. In some embodiments, the anticoagulant is sprayed and dried on the blood collection tube, container, or vessel prior to drawing a blood sample from the subject. In some embodiments, the anticoagulant is added directly to the formulation described herein.
[0026] In certain embodiments, the pH buffer is Tris-HCl, the polyol is a pentose alcohol, the non-reducing sugar is trehalose, the anticoagulant is EDTA or hirudin, and the functional carbohydrate is sucrose octasulfate. In certain embodiments, the pH buffer is Tris-HCl, the polyol is adonitol, the non-reducing sugar is the D+ isomer of trehalose, the anticoagulant is EDTA or hirudin, and the functional carbohydrate is sucrose octasulfate. In certain embodiments, the pH buffer is Tri-HCl, the polyol is adonitol, the non-reducing sugar is the D+ isomer of trehalose, the anticoagulant is hirudin, and the functional carbohydrate is sucrose octasulfate. In some embodiments, the disaccharide derivative is a halogenated disaccharide and the anticoagulant is hirudin. In some embodiments, the halogenated disaccharide is sucralose and the anticoagulant is hirudin.
[0027] In some embodiments, formulations for substantially stable storage of inactivated platelets at ambient temperature include exemplary formulations provided in Table 1.
[0028] [Table 1]
[0029] In some embodiments, exemplary formulations (AF) in Table 1 are prepared using commercially available materials from suppliers, and preparation of such formulations is accomplished using methods disclosed herein and other methods known to those of skill in the art.
[0030] In some embodiments, the pre-weighed solid components are added to a suitable container, such as a square bottle, to which the aqueous components are added. The reaction mixture is stirred, for example by shaking, until the solid components are completely dissolved, and then the pH of the mixture is adjusted to the desired pH using a suitable acid, for example, hydrochloric acid. The resulting formulation is then sterilized, for example, using a 0.22 micron filter, and stored at room temperature.
[0031] In one example, a 50 mL preparation of 20X Formula A is prepared as follows: 15.2034 gr of Adonitol (Calbiochem, Cat #121739) and 1.251 g of sucrose octasulfate potassium salt (Toronto Research Chemicals, Cat #S69900) are added to a square bottle. A volume of 30 mL of water is added, followed by 2.5 mL of Tris-HCl (Invitrogen Cat #15567-027). Additional water is added qc to the formulation until the final volume is 50 mL. The mixture is shaken until completely dissolved, and the pH is adjusted to 7.51 by adding hydrochloric acid. The resulting formulation is obtained by sterile filtering the solution under vacuum (0.22 μm pore size).
[0032] In another example, a 50 mL preparation of 20X Formula B is prepared as follows: 7.5994 g of adonitol, 9.4997 g of D-(+)-trehalose dihydrate (Fluka, catalog #90210), and 1.25 g of sucrose octasulfate potassium salt are added to a square bottle. A volume of 30 mL of water is added, followed by 2.5 mL of Tris-HCl (Invitrogen catalog #15567-027). Additional water is added qc to the formulation until the final volume is 50 mL. The mixture is shaken until completely dissolved, and the pH is adjusted to 7.51 by adding hydrochloric acid. The solution is sterile filtered under vacuum (0.22 μm pore size) to obtain the resulting formulation.
[0033] In another example, a 50 mL preparation of 20X Formula C is prepared as follows: 9.5003 g of D-(+)-trehalose dihydrate and 1.2502 g of sucrose octasulfate potassium salt are added to a square bottle. A volume of 30 mL of water is added, followed by 2.5 mL of Tris-HCl (Invitrogen catalog #15567-027). Additional water is added qc to the formulation until the final volume is 50 mL. The mixture is shaken until completely dissolved, and the pH is adjusted to 7.52 by adding hydrochloric acid. The solution is sterile filtered under vacuum (0.22 μm pore size) to obtain the resulting formulation.
[0034] In another example, a 50 mL preparation of 20X Formula D is prepared as follows: 7.5994 g adonitol, 9.5003 g D-(+)-trehalose dihydrate, and 0.625 g sucrose octasulfate potassium salt. A volume of 30 mL of water is added, followed by 2.5 mL of Tris-HCl (Invitrogen catalog #15567-027). Additional water is added qc to the formulation until the final volume is 50 mL. The mixture is shaken until completely dissolved, and the pH is adjusted to 7.51 by adding hydrochloric acid. The solution is sterile filtered under vacuum (0.22 μm pore size) to obtain the resulting formulation.
[0035] In another example, a 50 mL preparation of 20X Formula E is prepared as follows: 9.9997 g of sucralose (Sigma catalog #69293) is added to a square bottle. A volume of 30 mL of water is added, followed by 2.5 mL of Tris-HCl (Invitrogen catalog #15567-027). Additional water is added qc to the formulation until the final volume is 50 mL. The mixture is shaken until fully dissolved, and the pH is adjusted to 7.54 by adding hydrochloric acid. The solution is sterile filtered under vacuum (0.22 μm pore size) to obtain the resulting formulation.
[0036] In another example, a 50 mL preparation of 20X Formula F is prepared as follows: 9.9993 g of sucralose (Sigma catalog #69293) is added to a square bottle. Water is added qc to the formulation until the final volume is 50 mL. The mixture is shaken until fully dissolved to provide a solution with a pH of 7.54. The solution is sterile filtered under vacuum (0.22 μm pore size) to obtain the resulting formulation. (Purified stabilized platelets) In some embodiments, one or more substantially stabilized platelets in a blood sample at ambient temperature are purified using known methods used by those skilled in the art. Devices and kits for removing blood from platelets are known (see, for example, U.S. Patent Nos. 5,234,593, 6,315,706, and 7,708,152). In certain embodiments, platelets are purified using bag PC (concentrated platelets) prepared after blood collection in a bag and apheresis PC obtained using a blood component collection device. Such methods use centrifugation to separate platelets from blood. In some embodiments, substantially stabilized, intact, metabolically active live cells are advantageously purified by affinity chromatography or fluorescence-activated cell sorting (FACS) analysis using antibodies generated against native wild-type membrane proteins and receptors, which cannot occur using other preservation formulations that denature these cellular proteins.
[0037] In some embodiments, the purified platelet or platelets are then stored in a formulation described herein for an extended period of time prior to analysis or use. (product) In certain embodiments, an article of manufacture is provided that includes a formulation provided herein, placed into a suitable blood collection tube, container, or vessel. In some embodiments, the formulation is selected from those described in Table 1. In some embodiments, such an article is used for substantially stable storage of one or more blood components by stabilizing the one or more blood components upon collection. In certain embodiments, the blood collection tube is an evacuated blood collection tube having a subatmospheric pressure to draw a predetermined volume of whole blood. In some embodiments, such an article is used in the kits and methods described herein. (kit) In certain embodiments, a kit is provided that includes any one of the products and package inserts described herein. In some embodiments, the components of the kit are enclosed in a packaging means, such as a compartmented plastic enclosure, preferably in a sealable cover, such that the contents of the kit can be preserved by sterilization and containment. Method for substantially stable storage of one or more platelets in a blood sample at ambient temperature Described herein, in some embodiments, are methods for substantially stably storing one or more platelets at ambient temperature. In some embodiments, the methods are for substantially stably storing one or more platelets in an inactivated state in a blood sample at ambient temperature.
[0038] In certain embodiments, the method includes mixing the blood sample with a formulation for substantially stable storage of one or more platelets at ambient temperature for at least 6 hours. In some embodiments, the one or more platelets are isolated from the blood sample. In some embodiments, the one or more platelets are stabilized in an inactivated state. In some embodiments, at least 90% of the platelets remain in an inactivated state for at least 6 hours. In other embodiments, the platelets are stabilized in an inactivated state for at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours, or at least 24 hours. In certain embodiments, the formulation is one of the formulations described in Table 1.
[0039] In certain embodiments, the method comprises mixing the blood sample with a formulation for substantially stable preservation of viable activatable platelets, the formulation comprising a pH buffer, an anticoagulant, a non-reducing sugar, a polyol, and a functional carbohydrate. In certain embodiments, the platelet stabilizing formulation comprises a pH buffer, an anticoagulant, a polyol, and a functional carbohydrate. In certain embodiments, the stabilizing formulation comprises a pH buffer, an anticoagulant, a non-reducing sugar, and a functional carbohydrate. In yet another embodiment, the stabilizing formulation comprises a halogenated disaccharide derivative and an anticoagulant. In yet another embodiment, the stabilizing formulation comprises a halogenated disaccharide derivative, and the anticoagulant further comprises a pH buffer. In certain embodiments, the formulation is one of the formulations described in Table 1.
[0040] In certain embodiments, the method comprises mixing the blood sample with a formulation for substantially stable preservation of viable activatable platelets in the blood sample, the formulation comprising a pH buffer, an anticoagulant, a non-reducing sugar, a polyol, and a functional carbohydrate. In certain embodiments, the platelet stabilizing formulation comprises a pH buffer, an anticoagulant, a polyol, and a functional carbohydrate. In certain other embodiments, the stabilizing formulation comprises a pH buffer, an anticoagulant, a non-reducing sugar, and a functional carbohydrate. In yet another embodiment, the stabilizing formulation comprises a halogenated disaccharide derivative and an anticoagulant. In yet another embodiment, the stabilizing formulation further comprises a pH buffer. In certain embodiments, the formulation is one of the formulations described in Table 1.
[0041] Blood collection tubes, bags, containers, and vessels are well known in the art and have been used by physicians for decades. Blood collected for substantially stable storage of one or more blood components may be obtained from a subject, donor, or patient using any method or device commonly used by those skilled in the art, such as venipuncture or finger prick. In some embodiments, when blood is collected by venipuncture, the formulations described herein are positioned inside a blood collection tube, e.g., an evacuated tube (Vacutainer, Becton Dickinson, or Vacuette, Greiner), when obtaining a blood sample from a donor or patient. In some embodiments, the stabilizing formulation is added to a whole blood sample that has already been obtained, preferably immediately or shortly after it is drawn.
[0042] In some embodiments, the methods described herein use the disclosed articles of manufacture and kits.
[0043] The following examples are offered by way of illustration and not by way of limitation. Example 1: Stabilization of inactive platelets in human blood samples for at least 22 hours at ambient temperature This example describes a formulation of the invention for stabilizing inactivated platelets that can remain activated after storage at ambient temperature for 22 hours.
[0044] Stored blood samples were collected from six human donors using commercially available hirudin-coated blood collection tubes (Roche Diagnostics), the blood samples were pooled, and the blood samples were processed within 3 hours after collection. A 300 μL aliquot of each whole blood sample was transferred to an Eppendorf tube containing 15 μL of stabilizer formulation A, B, C, or D from Table 1 in a 1:20 ratio, and the mixtures were kept at ambient temperature for a predetermined time before analysis, either before or after the addition of the stabilizer formulation. An equal volume of whole blood was added to each control sample, and each sample was stored at room temperature without the stabilizer formulation and processed in parallel with the test samples.
[0045] To 300 μL of each mixture and control, 300 μL of NaCl 0.9% and 20 μL of the provided ADP solution were added to stimulate platelet activation, and samples were analyzed using a multiplate analyzer (Roche Diagnostics). Platelet activity for each condition was measured immediately after sample placement (time 0) using the multiplate analyzer and ADP test according to the manufacturer's instructions. Platelet activity was measured at 3, 6, 9, and 22 hours. Platelet activity under each condition was normalized to the measurement at time 0. Data from the six donors were then averaged. Data are shown in Table 2.
[0046] [Table 2]
[0047] As shown in Table 2, after 9 hours of incubation, the mean decrease in platelet activity under NF control conditions was -23% compared to +15%, +14%, +1%, and -7% for formulations A, B, C, and D, respectively, in Table 2. Significant platelet activity was still detected after 22 hours of incubation, with a mean decrease in platelet activity under NF control conditions of -41%, compared to -9%, -8%, -26%, and -10% for formulations A, B, C, and D, respectively, in Table 2.
[0048] The formulations in Table 1 containing the halogenated disaccharide derivative (sucralose) were characterized as described above and were also found to have stable platelet activity in whole blood for at least 22 hours (Table 3). In this study, the formulations as described above were placed in hirudin evacuated blood collection tubes prior to blood collection, as described in Table 1.
[0049] [Table 3]
[0050] During blood incubation at room temperature, platelet activity under NF control conditions was reduced by -40% at 22 hours, compared to -3% for Formula F and -27% for Formula E in Table 1.
[0051] Unless the context requires otherwise, throughout this specification and claims, the word "comprises" and variations thereof, such as "comprises" and "comprising," are used interchangeably with "including," "containing," or "characterized by" and are inclusive or open-ended terms and do not exclude additional, unrecited elements or method steps. The phrase "consisting of" excludes any element, step, or ingredient not specified in the claim. The phrase "consisting essentially of" limits the scope of the claim to those materials or steps specified or that do not materially affect the basic and novel characteristics of the subject invention. This disclosure contemplates embodiments of the compositions and methods of the invention that fall within the scope of each of these phrases. Thus, a composition or method that includes a recited element or step contemplates certain embodiments in which the composition or method consists essentially of or consists of such elements or steps.
[0052] References throughout the specification to "one embodiment" or "embodiment" or "aspect" mean that a particular feature, structure, or characteristic described in connection with an embodiment is included in at least one embodiment of the invention. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout the specification are not necessarily all referring to the same embodiment. Furthermore, particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0053] The various embodiments described above can be combined to provide further embodiments. Any modifications to the embodiments can be made in light of the above detailed description. In general, in the following claims, the terms should not be construed to limit the claims to the specific embodiments disclosed in the specification and claims, but should be construed to include all embodiments to the full scope of equivalents to which such claims are entitled. Thus, the claims are not limited by this disclosure.
[0054] From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the invention is not to be limited except as by the appended claims.
[0055] Moreover, the present invention may be the inventions described in the following items [1] to
[42] . [1] A formulation for substantially stable storage of one or more platelets at ambient temperature, wherein the one or more platelets are stabilized for at least six hours. [2] The formulation of [1], wherein the one or more platelets are stabilized in an inactivated state. [3] The formulation of [1] or [2], wherein the one or more platelets are present in a blood sample. [4] The formulation described in any one of [1] and [2], wherein the one or more platelets are isolated from a blood sample. [5] A formulation described in any one of [1] to [4], wherein at least 90% of the platelets are stabilized in an inactivated state for at least 6 hours. [6] A formulation described in any one of [1] to [5], wherein at least 90% of the platelets are stabilized in an inactivated state for at least 9 hours. [7] The formulation is (i) pH buffer; (ii) anticoagulants; (iii) at least one non-reducing sugar or polyol; and (iv) functional carbohydrates; The formulation according to any one of [1] to [6], [8] The formulation of any one of [1] to [7], wherein the formulation comprises a polyol selected from the group consisting of glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, adonitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, and combinations thereof. [9] The formulation according to any one of [1] to [7], wherein the formulation contains a pentose polyol or a hexose polyol.
[10] The formulation described in [9], wherein the pentose polyol is adonitol.
[11] The formulation according to any one of [7] to
[10] , wherein the functional carbohydrate is sucralfate or sucrose octasulfate.
[12] The formulation according to any one of [7] to
[10] , wherein the functional carbohydrate is sucrose octasulfate.
[13] The formulation according to any one of [7] to
[12] , wherein the non-reducing sugar is sucrose or trehalose.
[14] The formulation according to any one of [7] to
[12] , wherein the non-reducing sugar is trehalose.
[15] A formulation described in any one of [7] to
[14] , wherein the anticoagulant is EDTA or hirudin.
[16] The formulation according to any one of [7] to
[15] , wherein the pH buffer is 2x phosphate buffered saline or Tris-HCl.
[17] A formulation for substantially stable storage of one or more platelets at ambient temperature, the formulation comprising a halogenated disaccharide derivative and an anticoagulant, wherein the one or more platelets are stabilized for at least six hours.
[18] The formulation described in
[17] , wherein one or more platelets are stabilized in an inactivated state.
[19] The preparation of
[17] or
[18] , wherein one or more platelets are present in the blood sample.
[20] The preparation of any one of
[17] and
[18] , wherein the one or more platelets are isolated from a blood sample.
[21] A formulation according to any one of
[17] to
[20] , wherein the anticoagulant is hirudin.
[22] The formulation of any one of
[17] to
[21] , wherein the halogenated disaccharide derivative is selected from the group consisting of sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside), trichloronatomaltose, 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside, 1,6-cyclo-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside, and combinations thereof.
[23] The formulation described in
[17] , wherein the formulation consists essentially of hirudin and sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside).
[24] A composition of one or more platelets substantially stably stored in an inactivated state, comprising one or more platelets mixed with any one of the preparations described in [1] to
[23] .
[25] The composition of
[24] , wherein one or more platelets are present in a blood sample.
[26] The composition described in
[24] , wherein one or more platelets are isolated platelets.
[27] A product comprising: A product comprising any one of the formulations [1] to
[23] contained in a blood collection tube.
[28] The product according to
[20] , wherein the blood collection tube is an evacuated blood collection tube.
[29] A kit comprising the product according to
[27] or
[28] and an insert.
[30] A method for substantially stably storing one or more platelets at ambient temperature, the method comprising: mixing one or more platelets from a subject with any one of the preparations of [1] to
[23] , wherein the one or more platelets are stabilized for at least six hours.
[31] The method of
[30] , wherein one or more platelets are stabilized in an inactivated state.
[32] The method of
[30] or
[31] , wherein one or more platelets are present in a blood sample from the subject.
[33] The method of any one of
[30] and
[31] , wherein one or more platelets are isolated from a blood sample from the subject.
[34] The method according to any one of
[30] to
[33] , wherein at least 90% of the platelets are stabilized in an inactivated state for at least 6 hours.
[35] The method according to any one of
[30] to
[34] , wherein at least 90% of the platelets are stabilized in an inactivated state for at least 9 hours.
[36] The method of any one of
[30] to
[35] , further comprising the step of activating one or more platelets by adding an activating agent to promote platelet aggregation.
[37] The method according to
[36] , wherein the activator is ADP.
[38] The method of any one of
[30] to
[37] , further comprising the step of activating one or more platelets by adding an activating agent to promote platelet aggregation.
[39] The method according to
[38] , wherein the activator is ADP.
[40] The method according to any one of
[30] to
[39] , wherein the subject is an animal.
[41] The method according to any one of
[30] to
[40] , wherein the subject is a mammal.
[42] The method according to
[41] , wherein the mammal is a human.
Claims
1. A formulation for the stabilization of one or more platelets at ambient temperature, comprising: (i) pH buffer; (ii) halogenated disaccharide derivatives; and (iii) polyol; Including, The formulation, wherein the halogenated disaccharide derivative is a dichlorinated or trichlorinated disaccharide.
2. 2. The formulation of claim 1, wherein the pH buffer comprises Tris-HCl, citric acid, or 2x phosphate buffered saline.
3. 3. The formulation of claim 1 or 2, wherein the pH of the formulation is in the range of about 4.0 to about 9.
0.
4. 4. The formulation of claim 1, wherein the halogenated disaccharide derivative is selected from the group consisting of 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside, trichloronatomaltose, 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside, 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside, and combinations thereof.
5. 5. The formulation according to any one of claims 1 to 4, wherein the polyol is selected from the group consisting of glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, adonitol, mannitol, sorbitol, galactitol, fucitol, iditol and inositol, and combinations and derivatives thereof.
6. The formulation of any one of claims 1 to 5, wherein the polyol is present at a concentration of about 20 mM to about 100 mM.
7. The formulation of any one of claims 1 to 6, wherein the polyol is present at a concentration of about 25 mM to about 75 mM.
8. further comprising at least one of a functional carbohydrate, a non-reducing sugar, and an anticoagulant; The formulation of any one of claims 1 to 7, wherein the functional carbohydrate is sucralfate, sucrose octasulfate, or a combination thereof.
9. 9. The formulation of claim 8, wherein the non-reducing sugar is sucrose, trehalose, or a combination thereof.
10. 10. The formulation of claim 8 or 9, wherein the anticoagulant is selected from the group consisting of ethylenediaminetetraacetic acid, hirudin, heparin, and sodium citrate, and combinations thereof.
11. A method for stabilizing one or more other components in a blood sample, The formulation of any one of claims 1 to 10, wherein the one or more further components are selected from the group consisting of cells, nucleic acid molecules, peptides and polypeptides, and combinations thereof.
12. 12. The formulation of claim 1, wherein the formulation is added to the blood sample in a formulation:blood sample ratio of about 1:10 to about 1:
20.
13. A blood collection tube comprising the formulation according to any one of claims 1 to 12.
14. A kit comprising the blood collection tube of claim 13 and an attached instruction manual.
15. 1. A method for stabilizing one or more platelets at ambient temperature, comprising: mixing a blood sample from a subject with a preparation to obtain a mixture, The formulation comprises: (i) pH buffer; (ii) halogenated disaccharide derivatives, and (iii) a polyol, and storing the mixture at ambient temperature for at least 6 hours; Including, The method of claim 1, wherein the halogenated disaccharide derivative is a dichlorinated or trichlorinated disaccharide.
16. 16. The method of claim 15, wherein the pH buffer comprises Tris-HCl, citrate, or 2x phosphate buffered saline.
17. 17. The method of claim 15 or 16, wherein the polyol is selected from the group consisting of glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, adonitol, mannitol, sorbitol, galactitol, fucitol, iditol and inositol, and combinations and derivatives thereof.
18. 18. The method of any one of claims 15 to 17, wherein the polyol is present at a concentration of about 20 mM to about 100 mM.
19. 19. The method of any one of claims 15 to 18, wherein the polyol is present at a concentration of about 25 mM to about 75 mM.
20. the formulation further comprises at least one of a functional carbohydrate, a non-reducing sugar, and an anticoagulant; 20. The method of any one of claims 15 to 19, wherein the functional carbohydrate is sucralfate, sucrose octasulfate, or a combination thereof.
21. One or more other components of the blood sample are stabilized in the mixture; The method of any one of claims 15 to 20, wherein the one or more further components are selected from the group consisting of cells, nucleic acid molecules, peptides and polypeptides, and combinations thereof.
Citation Information
Patent Citations
Platelet preservation liquid
JP1997087183A
Method for preparing fully filtered stabilized blood product
JP2002512968A
Blood collection device containing blood stabilizers
JP2014506319A
Anticoagulant compounds
WO1994022885A1
